Clinical efficacy of TCM syndrome differentiation in the treatment of severe/critical type of novel coronavirus pneumonia (COVID-19): a prospective, observational, one-arm clinical study

Hospital of Chengdu University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Patients with severe and critical COVID-19 diagnosed in accordance with the Novel Coronavirus infected Pneumonia Diagnosis and Treatment Plan (Trial Version 6);
•2. Aged >=18 years, both men and women;
•3. Agree to participate in this test and sign the informed consent.

•1. Those who cannot receive Chinese medicine treatment;
•2. Patients with allergies to certain traditional Chinese medicine decoctions or traditional Chinese medicine injections;
•3. Cases where complete diagnosis and treatment information cannot be obtained;
•4. Any other chronic respiratory diseases, respiratory bacterial infections such as purulent tonsillitis, acute tracheobronchitis, sinusitis, otitis media, and other respiratory diseases affecting clinical trial evaluation;
•5. Accompanied by basic diseases such as severe primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformation, congenital heart disease, and abnormal lung development;
•6. Expected survival time is less than 1 week.
•Note: Anyone who meets any of the above exclusion criteria cannot be included in this test.

发起方

Hospital of Chengdu University of Traditional Chinese Medicine